Silodosin improves functional consequences of lower urinary tract obstruction secondary to benign prostate hypertrophy, a proof of concept study in the spontaneously hypertensive rat supplemented with testosterone.

Autor: Assaly R; Pelvipharm, Montigny-le-Bretonneux, France.; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France., Faugeroux J; Pelvipharm, Montigny-le-Bretonneux, France.; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France., Laurin M; Pelvipharm, Montigny-le-Bretonneux, France.; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France., Compagnie S; Pelvipharm, Montigny-le-Bretonneux, France.; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France., Alexandre L; Pelvipharm, Montigny-le-Bretonneux, France., Giuliano F; Pelvipharm, Montigny-le-Bretonneux, France.; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France.; AP-HP, Neuro-Uro-Andrology, Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, Garches, France., Behr-Roussel D; Pelvipharm, Montigny-le-Bretonneux, France. d.behr.roussel@pelvipharm.com.; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France. d.behr.roussel@pelvipharm.com.
Jazyk: angličtina
Zdroj: BMC urology [BMC Urol] 2020 Aug 27; Vol. 20 (1), pp. 132. Date of Electronic Publication: 2020 Aug 27.
DOI: 10.1186/s12894-020-00699-y
Abstrakt: Background: The main purpose of this study is to investigate the effect of silodosin on the urodynamic consequences in a previously established model of lower urinary tract symptoms associated with benign prostate hyperplasia, the spontaneously hypertensive rats (SHR) supplemented with testosterone.
Methods: Three groups of animals (8-week-old; n = 10/group) were considered: Wistar Kyoto (control) rats (WKY), SHR supplemented with testosterone at 3 mg/kg/day and treated with either vehicle (SHR-T, n = 10) or silodosin at 0.1 mg/kg/day (SHR-T + silodosin, n = 10) by oral gavage for 6 weeks. Cystometry experiments were performed. The bladder was harvested, weighed and paraffin-embedded for morphometric analysis. The prostate was also harvested and weighed.
Results: The number of animals included in the analysis were n = 10/10 for WKY and n = 7-8/10 for each SHR rats supplemented with testosterone group. SHR-T displayed a significant decrease in the intercontraction interval, infused volume and mean flow rate whereas the frequency of non-voiding contractions was increased. Silodosin improved the voiding behavior of SHR-T by significantly increasing the intercontraction interval, the infused volume and the mean flow rate and decreasing the number of non-voiding contractions. SHR-T displayed a significant increase in prostate and bladder weights and a 15% increase in the detrusor wall area compared to WKY.
Conclusions: Chronic silodosin treatment relieved storage symptoms in SHR supplemented with testosterone and decreased the frequency of non-voiding detrusor contractions during the filling phase.
Databáze: MEDLINE
Externí odkaz: